GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Synlogic Inc.
Synlogic is a pioneer in synthetic biology, developing living drugs based on modified bacteria. Its stock price is a venture bet on this revolutionary technology. The chart reflects high volatility and dependence on lab news.
Share prices of companies in the market segment - Pharma metabolism
Synlogic uses synthetic biology to create living drugs—genetically engineered bacteria that treat metabolic and inflammatory diseases. We've categorized it under "Pharma: Metabolism." The chart below shows how investors view this breakthrough approach to medicine.
Broad Market Index - GURU.Markets
Synlogic is a biotech company developing a new class of drugs based on synthetic probiotics for the treatment of metabolic diseases. As a pioneer, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Synlogic's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
SYBX - Daily change in the company's share price Synlogic Inc.
For Synlogic, Inc., a company that develops synthetic biotics, daily price change is a measure of enormous volatility. This metric reflects extreme sensitivity to clinical trial data and is key to risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Synlogic, Inc. is a biotech company. This chart demonstrates the extreme volatility of the sector. Comparison with SYBX, with its unique synthetic biology platform, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Synlogic is a pioneer in developing drugs based on synthetic biotics—"smart" bacteria—for the treatment of metabolic diseases. The company's shares are a bet on scientific revolution. Their high volatility is part of the dynamic nature of the innovation sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Synlogic Inc.
For Synlogic, Inc., the year-to-date performance is a story about the development of an innovative synthetic biology platform. Its 12-month market cap depends on clinical trial data for its "live" drugs, which are modified bacteria for the treatment of metabolic diseases. Success will demonstrate the potential of this revolutionary approach.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Synlogic, Inc. is a biotechnology company developing a unique class of "living" drugs based on synthetic bacteria. Its stock price is extremely volatile, reflecting investor confidence in its breakthrough scientific platform rather than its current financial performance, which is typical for this speculative sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Synlogic operates at the forefront of science, creating "living medicines." Its shares are a venture investment in a technology platform. The graph of its returns relative to the market shows that investors are buying not current profits, but the hope of a revolution in medicine. Therefore, its performance is completely unrelated to general economic cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Synlogic Inc.
Synlogic develops innovative drugs based on synthetic biotics. Being in the clinical stage, its monthly evaluation is entirely dependent on news. Trial results confirming the viability of its unique technological platform are the main driver.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
This chart reflects the dynamics of the cutting-edge biotech sector. For Synlogic, a pioneer in synthetic biotics, it's the backdrop. Its movements demonstrate how successes in clinical trials and FDA approvals can create powerful trends for this entire emerging niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Biotechnology, which uses synthetic microbes to treat diseases, is at the cutting edge of science. The chart below shows investors' overall risk appetite. Is Synlogic, Inc. moving in sync with the market, or is its performance driven solely by scientific breakthroughs, ignoring broader trends?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Synlogic Inc.
Synlogic, a pioneer in synthetic biota for the treatment of metabolic diseases, is extremely volatile. Its weekly stock price is a direct reaction to clinical trial data from its drugs, which are live bacteria programmed to perform therapeutic functions in the gut.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Synlogic operates in the revolutionary synthetic biology sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment. The chart will show whether SYBX is perceived by the market as a leader in this movement or simply part of it.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Synlogic, Inc., as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how SYBX shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
SYBX - Market capitalization of the company Synlogic Inc.
Synlogic's chart is a visual representation of a groundbreaking approach to treating metabolic diseases. The company develops "synthetic biotics"—genetically engineered bacteria designed to perform therapeutic functions in the gut. Its market capitalization dynamics represent a speculative bet on this futuristic yet risky science.
SYBX - Share of the company's market capitalization Synlogic Inc. within the market segment - Pharma metabolism
Synlogic uses synthetic biology to create a new class of "living" drugs—bacteria programmed to treat metabolic and inflammatory diseases. Its market share is based on this breakthrough approach. The chart shows how the market assesses its chances of creating a completely new therapeutic modality.
Market capitalization of the market segment - Pharma metabolism
Synlogic uses synthetic biology to create "living drugs"—modified bacteria that treat metabolic diseases from the inside out. The chart below shows the market capitalization of this disruptive sector. Its dynamics are a bet on a revolution in medicine.
Market capitalization of all companies included in a broad market index - GURU.Markets
Synlogic is a pioneer in synthetic biology, programming beneficial bacteria to treat metabolic and immunological diseases. Its market cap is a bet on this breakthrough. The chart below shows the growing economic weight of the living drug sector.
Book value capitalization of the company, segment and market as a whole
SYBX - Book value capitalization of the company Synlogic Inc.
Synlogic is built on a unique biotechnology platform. The company's book value reflects its patents for the technology it holds for creating "synthetic biotics"—live bacteria programmed to treat metabolic diseases—and the capital it invests in their R&D. The chart below shows the financial basis for this cutting-edge research.
SYBX - Share of the company's book capitalization Synlogic Inc. within the market segment - Pharma metabolism
Synlogic, Inc. relies on its R&D laboratories and manufacturing facilities to develop synthetic biotics. The S_BCap_Seg graph shows its share of the physical infrastructure of the innovative biotech sector.
Market segment balance sheet capitalization - Pharma metabolism
Synlogic uses synthetic biology to create "living medicines." Its assets are not factories, but a unique scientific platform and patents. The chart shows that its balance sheet is virtually devoid of tangible assets, typical for a company at the forefront of biotechnology.
Book value of all companies included in the broad market index - GURU.Markets
Synlogic's assets comprise a pioneering platform for "living medicines." The company's book value reflects its laboratories and pilot plant, where genetically engineered bacteria are created to treat metabolic diseases. This represents tangible capital invested in the development of a fundamentally new class of therapeutics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Synlogic Inc.
Synlogic is a biotech company developing "living drugs" based on synthetic biotics (modified bacteria). Its book value is derived from R&D investments. Its market capitalization is a pure valuation of its revolutionary scientific platform and its potential to treat metabolic diseases.
Market to book capitalization ratio in a market segment - Pharma metabolism
Synlogic is a biotech company that creates "synthetic biotics"—living drugs for the treatment of metabolic diseases. This is a breakthrough technology. The chart shows the market premium for its unique scientific platform compared to the value of its laboratories.
Market to book capitalization ratio for the market as a whole
Synlogic is a pioneer in synthetic biology, developing "living drugs" based on modified bacteria. The company's value is based on the potential of this revolutionary platform. The chart illustrates how far investor expectations are driving its market capitalization away from its modest book value.
Debts of the company, segment and market as a whole
SYBX - Company debts Synlogic Inc.
Synlogic, a company developing synthetic biotics, is using debt to finance its innovative scientific platform. This chart shows the capital raised to conduct clinical trials of programmable bacteria for the treatment of metabolic diseases. This is a long-term, high-risk bet on a new class of drugs.
Market segment debts - Pharma metabolism
Synlogic is a biotech company developing a new class of living drugs based on synthetic biology for the treatment of metabolic diseases. This cutting-edge science requires significant, long-term investment. This chart shows its financial position and how it uses equity capital to fund its unique R&D.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Synlogic Inc.
Synlogic develops innovative drugs based on synthetic biotics. This chart shows how the company finances its cutting-edge research. In the emerging field of synthetic biology, where commercial success has yet to be proven, raising debt is a sign of extreme confidence in the technology, but also carries enormous risk.
Market segment debt to market segment book capitalization - Pharma metabolism
Synlogic, Inc. is a pioneer in the development of synthetic biotic-based drugs for the treatment of metabolic diseases. This chart for the cutting-edge biotech industry shows how much capital it raises to fund breakthrough research. It provides context for assessing the company's financial strategy in this innovative field.
Debt to book value of all companies in the market
Synlogic uses synthetic biology to create a new class of drugs—living therapeutics for the treatment of metabolic diseases. This chart, showing the market's debt-to-book value ratio, is important for assessing the investment climate. The market's willingness to finance breakthrough but risky technologies determines Synlogic's ability to move forward.
P/E of the company, segment and market as a whole
P/E - Synlogic Inc.
Synlogic uses synthetic biology to create "living drugs"—genetically modified bacteria designed to treat metabolic and immune diseases. This chart reflects its belief in breakthrough science. Its value indicates the extent to which investors are willing to back this futuristic approach, which could revolutionize medicine.
P/E of the market segment - Pharma metabolism
Synlogic, Inc. is a biotech company. This chart shows the average P/E ratio for the biotech sector. A company's P/E is higher than average, indicating that investors consider its "living drug" platform particularly disruptive and are willing to pay a premium for its potential compared to other biotechs.
P/E of the market as a whole
Synlogic is a pioneer in synthetic biology, developing "living drugs"—genetically engineered bacteria—to treat metabolic and immune diseases. This chart illustrates the risk appetite in biotech. The company's valuation is based on investors' belief in the breakthrough potential of this completely new therapeutic modality, which comes with very high scientific and clinical risks.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Synlogic Inc.
Synlogic is developing a new class of drugs (synthetic biotics) based on engineered bacteria for the treatment of metabolic diseases. The chart reflects investor expectations for this innovative platform. Future revenue is entirely dependent on the success of clinical trials and proof of the effectiveness of this approach.
%20P%2FE%20Synlogic%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Synlogic-Inc.&v=1772671293376 "Chart of the company's future (projected) P/E Synlogic Inc.")
Future (projected) P/E of the market segment - Pharma metabolism
Synlogic uses synthetic biology to create a new class of living drugs—synthetic biotics—that perform therapeutic functions in the gut to treat metabolic diseases. This chart shows its future profitability expectations, allowing us to assess how highly the market values its breakthrough platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772671293393 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Synlogic is a biotech company developing a new class of drugs based on synthetic probiotics that treat metabolic diseases from within the gut. This is cutting-edge science. The company's valuation is not tied to general market forecasts, but depends entirely on the success of its unique platform.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772671293407 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Synlogic Inc.
Synlogic, Inc. is a pioneer in developing a new class of drugs based on genetically modified bacteria (synthetic biotics) for the treatment of metabolic and immunological diseases. While in the clinical stage, the company incurs significant expenses. This chart reflects its investment in a breakthrough scientific platform that has the potential to transform treatment approaches.
Profit of companies in the market segment - Pharma metabolism
Synlogic, Inc. is a pioneer in the development of a new class of drugs—synthetic biotics, which are living bacteria engineered to perform therapeutic functions in the body. This chart reflects the profitability of its segment. The company's R&D costs impact current profitability, but its breakthrough platform could create a completely new approach to treating metabolic diseases.
Overall market profit
Synlogic, Inc. is a pioneer in the development of synthetic biotics, a new class of drugs based on living bacteria, for the treatment of metabolic diseases. The company's value depends on the success of this breakthrough technology. This chart shows the state of the traditional economy, while Synlogic operates at the forefront of biotechnology, where completely new approaches to treatment are being developed.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Synlogic Inc.
Synlogic uses synthetic biology to create a new class of living drugs—programmed bacteria—to treat metabolic and immune diseases. This chart reflects analysts' long-term expectations for this revolutionary technology, demonstrating market confidence that the company will successfully demonstrate the safety and efficacy of its approach.
%20profit%20of%20the%20company%20Synlogic%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Synlogic-Inc.&v=1772671293470 "Graph of future (projected) profit of the company Synlogic Inc.")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Synlogic, Inc. is developing a new class of drugs—synthetic biotics, which are living bacteria engineered to perform therapeutic functions. This chart shows profitability forecasts for the metabolic pharmaceutical segment. It reflects expectations for breakthrough technologies that could transform treatment approaches.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772671293475 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Synlogic is a biotech company developing synthetic biotics. Their future depends on successful clinical trials and their ability to finance them. The overall market return forecast, reflected in the chart, influences investors' risk appetite. Economic optimism facilitates raising capital for such innovative projects.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772671293497 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Synlogic Inc.
Synlogic, Inc. is developing an innovative class of "synthetic biotics"—living drugs for the treatment of metabolic diseases. Currently in the research stage, the company has no revenue. Its valuation is based on investors' belief in the breakthrough potential of its scientific platform.
P/S market segment - Pharma metabolism
Synlogic, Inc. is a pioneer in the development of "synthetic biotics"—living therapeutics based on modified bacteria for the treatment of metabolic and immunological diseases. Their valuation is based on this breakthrough platform. The chart shows the premium investors place on their science and potential to create a new class of drugs.
P/S of the market as a whole
Synlogic uses synthetic biology to program bacteria to treat metabolic diseases. The company has no commercial revenue, and its valuation reflects its belief in the breakthrough potential of its unique platform. This chart, based on actual revenue, clearly demonstrates Synlogic's commitment to cutting-edge science.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Synlogic Inc.
Synlogic, Inc. is a pioneer in the development of "synthetic biotics"—genetically modified bacteria—for the treatment of metabolic and immunological diseases. This is cutting-edge science. This chart reflects investor expectations for future revenue from this completely new therapeutic modality if it proves safe and effective.
%20P%2FS%20Synlogic%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Synlogic-Inc.&v=1772671293752 "The graph of the company's future (projected) P/S Synlogic Inc.")
Future (projected) P/S of the market segment - Pharma metabolism
Synlogic, Inc. is a pioneer in the development of synthetic biotics, a new class of drugs based on living bacteria for the treatment of metabolic and immunological diseases. This chart shows how the market perceives the future commercial potential of its revolutionary platform, comparing it to other companies in the metabolic disease sector.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772671293835 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Synlogic is a company developing a new class of drugs based on synthetic probiotics that are "programmed" to perform specific therapeutic functions in the body. This graph shows revenue expectations for the entire market, and SYBX exemplifies the cutting edge of biotechnology, where science strives to use living organisms as medicines.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772671293882 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Synlogic Inc.
Synlogic, Inc. is a clinical-stage biopharmaceutical company developing a new class of synthetic biotic-based drugs for the treatment of metabolic diseases. Because its drugs are in development, the company has no sales revenue. Revenue in this chart may be related to collaboration fees with partners.
Sales of companies in the market segment - Pharma metabolism
Synlogic develops innovative "synthetic biotics"—living medicines. At this stage, its revenue likely comes from strategic partnerships with major pharmaceutical companies. This chart allows investors to assess the level of financial support, reflecting the industry's faith in its unique platform.
Overall market sales
Synlogic, Inc. is a pioneer in the development of synthetic biotics, a new class of drugs. The company's success depends on its ability to demonstrate the efficacy and safety of this innovative technology in clinical trials. This overall market situation is irrelevant to Synlogic's assessment, as it operates at the forefront of science.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Synlogic Inc.
Synlogic is developing a new class of drugs based on synthetic biotics (engineered bacteria) for the treatment of metabolic diseases. Its revenue forecast depends on the success of clinical trials. This chart shows analysts' speculative expectations for the commercial potential of its unique scientific platform.
%20sales%20of%20the%20company%20Synlogic%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Synlogic-Inc.&v=1772671294018 "Schedule of future (projected) sales of the company Synlogic Inc.")
Future (projected) sales of companies in the market segment - Pharma metabolism
Synlogic is developing a new class of synthetic biotic-based drugs for the treatment of metabolic and immunological diseases. This chart shows projected revenue for the metabolic drugs segment. It reflects the expected growth of this innovative pharmaceutical industry, which is important for assessing the potential of Synlogic's platform.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772671294034 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
Synlogic is a biotech company developing "living" drugs based on synthetic biotics for the treatment of metabolic diseases. Its future depends on the success of clinical trials. This graph of general market expectations does not directly impact demand, but reflects the investment climate, which is critical for attracting funds for breakthrough R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772671294063 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Synlogic Inc.
Synlogic is a biopharmaceutical company developing a new class of drugs based on synthetic biotics (modified bacteria) for the treatment of metabolic diseases. This chart reflects the financial implications of this cutting-edge science. Future profitability depends entirely on the success of its clinical programs.
Market segment marginality - Pharma metabolism
Synlogic, Inc. is a pioneer in developing a new class of drugs called synthetic biotics, which use genetically engineered bacteria to treat metabolic diseases. This chart illustrates the average profit margin in the biotech sector. It allows one to estimate the economic potential of Synlogic's revolutionary platform if it proves effective.
Market marginality as a whole
Synlogic, Inc. is a pioneer in the development of synthetic biotics—a new class of drugs based on engineered bacteria. This is at the cutting edge of science. This chart, showing the profitability of traditional industries, only highlights how revolutionary and risky investing in companies creating entirely new therapeutic platforms is.
Employees in the company, segment and market as a whole
Number of employees in the company Synlogic Inc.
Synlogic is a biotech company creating "living medicines" based on synthetic biotics. Its team of scientists is a pioneer in this new field of medicine. The growth on this chart reflects the progress of its unique scientific platform and the advancement of candidates through preclinical and clinical trials.
Share of the company's employees Synlogic Inc. within the market segment - Pharma metabolism
Synlogic, Inc. is a pioneer in developing a new class of synthetic biotic-based drugs for the treatment of metabolic and immunological diseases. This chart highlights its cutting-edge scientific approach. It reflects the proportion of synthetic biologists and researchers programming bacteria to perform therapeutic functions in the body that Synlogic brings together.
Number of employees in the market segment - Pharma metabolism
Synlogic, Inc. is a biopharmaceutical company developing a new class of drugs—synthetic biotics—based on live bacteria. This chart illustrates employment in the metabolic research sector. Growth in this cutting-edge field reflects breakthroughs in microbiome engineering for the treatment of metabolic and immunological diseases.
Number of employees in the market as a whole
Synlogic, Inc. is a biotechnology company developing a new class of drugs based on synthetic biotics. It is at the cutting edge of science, merging biology and engineering. This chart shows the overall employment landscape, where such pioneering companies, albeit in their early stages, are shaping the future of pharmaceuticals and medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Synlogic Inc. (SYBX)
Synlogic, Inc. uses synthetic biology to create living drugs. It's at the cutting edge of science. This chart illustrates the enormous value the market sees in this futuristic technology. The astronomical market cap per employee is a bet that the Synlogic team will create an entirely new class of drugs.
%20of%20the%20company%20Synlogic%20Inc.%20(SYBX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Synlogic-Inc.-SYBX&v=1772671294337 "Chart of market capitalization per employee (in thousands of dollars) of the company Synlogic Inc. (SYBX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Synlogic creates drugs using synthetic biology, programming bacteria to treat diseases. The market capitalization per employee in this revolutionary field reflects investors' faith in its unique scientific platform. This very high figure speaks to the enormous potential the market sees in this approach.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772671294362 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Synlogic is using synthetic biology to create a new class of living drugs—programmed bacteria for the treatment of metabolic and immunological diseases. This is at the absolute cutting edge of science. This graph reflects the enormous investor anticipation for the team's ability to commercialize this revolutionary platform.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772671294375 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Synlogic Inc. (SYBX)
Synlogic is a biotech company developing "living drugs"—genetically engineered bacteria to treat metabolic diseases. This is cutting-edge science. This chart, in negative territory, shows how much capital is being burned per scientist working on this innovative R&D platform.
%20Chart%20Synlogic%20Inc.%20(SYBX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Synlogic-Inc.-SYBX&v=1772671294383 "Company Profit Per Employee (in thousands of dollars) Chart Synlogic Inc. (SYBX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Synlogic, Inc. is developing a new class of drugs—synthetic biotics—using genetically engineered bacteria to treat metabolic and immunological diseases. This graph illustrates the potential of their revolutionary platform. It shows the enormous value this new approach to medicine could generate if successful, a measure of their scientific innovation.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772671294405 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Synlogic, Inc. is a biotechnology company developing "synthetic biotics" (genetically engineered bacteria) to treat metabolic diseases. This is cutting-edge science. This chart reflects the R&D intensity per scientist required to create and test this new class of living drugs before they reach market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772671294419 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Synlogic Inc. (SYBX)
Synlogic, Inc. is a biotech company developing living drugs based on synthetic biology. This graph isn't representative of the clinical trial stage. A lack of revenue per employee is normal. It reflects investment in breakthrough science. The success of the platform will lead to exponential growth of this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Synlogic-Inc.-SYBX&v=1772671294460 "Sales chart per company employee Synlogic Inc. (SYBX)")
Sales per employee in the market segment - Pharma metabolism
Synlogic (SYBX) is a biotech company developing "synthetic biotics"—live drugs (modified bacteria)—to treat metabolic diseases such as phenylketonuria. This chart shows the average revenue per employee in the pharmaceutical segment. For Synlogic, which is in the R&D stage, comparing to this benchmark (zero) underscores their focus on an innovative scientific platform.
Sales per employee for the market as a whole
Synlogic (SYBX) is a biotechnology company developing living drugs (synthetic biology). It is a clinical-stage R&D company. It has no revenue (excluding partner fees). This metric does not reflect operational efficiency. Attention is focused on the results of trials of their innovative platform.
Short shares by company, segment and market as a whole
Shares shorted by company Synlogic Inc. (SYBX)
Synlogic is a biotech company developing "synthetic biotics"—genetically engineered bacteria—to treat metabolic diseases. This is cutting-edge science, but risky. This chart shows the odds that this hypothesis won't work. "Bears" believe their bacterial drugs won't prove effective in humans.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Synlogic-Inc.-SYBX&v=1772671294492 "Short Shares Chart for the Company Synlogic Inc. (SYBX)")
Shares shorted by market segment - Pharma metabolism
Synlogic (SYBX) is a biotech company developing "living" drugs—genetically modified bacteria—to treat metabolic diseases. This chart highlights the pessimism in the sector. The surge in short positions across the industry is a bet that this scientific platform is not working. Investors don't believe these "smart bacteria" will be able to prove their effectiveness in the human body and expect clinical trials to fail.
Shares shorted by the overall market
Synlogic (SYBX) is a clinical-stage biotech. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, loss-making biotechs like SYBX in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Synlogic Inc. (SYBX)
Synlogic is a biotech company developing "synthetic biotics" (genetically engineered bacteria) to treat metabolic diseases. This approach is highly innovative. This indicator reflects the excitement surrounding breakthrough technologies. It could overheat to the extreme on any data confirming the viability of their platform.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Synlogic-Inc.-SYBX&v=1772671294536 "RSI 14 indicator chart for the company's stock Synlogic Inc. (SYBX)")
RSI 14 Market Segment - Pharma metabolism
Synlogic is a pioneer in the field of "synthetic biotics." They program live bacteria (probiotics) to perform therapeutic functions within the body, such as treating metabolic diseases. This chart reflects the overall sentiment in the biotech sector and helps assess how the market as a whole views this innovative field.
RSI 14 for the overall market
Synlogic (SYBX) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the opportunity to easily raise hundreds of millions of dollars for research. Market panic poses the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SYBX (Synlogic Inc.)
Synlogic (SYBX) is a pioneer in the field of synthetic biology, programming living bacteria to treat rare metabolic diseases. This chart shows the average target price. It reflects analysts' highly speculative assessment of this cutting-edge scientific platform and its chances of success in clinical trials, which is key to the company's success.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SYBX-Synlogic-Inc.&v=1772671294545 "A chart showing analyst consensus forecasts for the expected stock price. SYBX (Synlogic Inc.)")
The difference between the consensus estimate and the actual stock price SYBX (Synlogic Inc.)
Synlogic is a pioneer in the field of "synthetic biota." The company programs live bacteria directly in the gut to treat rare metabolic diseases (such as phenylketonuria). This chart clearly demonstrates the gap between the current speculative price and the analyst consensus forecast. This gap, in essence, represents the experts' assessment of the chances that this revolutionary scientific platform will lead to a commercial drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SYBX-Synlogic-Inc.&v=1772671294583 "A chart showing the difference between the consensus forecast and the actual stock price. SYBX (Synlogic Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Synlogic is a "bio-programmer" creating "living drugs" (synthetic biotics) to treat rare metabolic diseases. This is cutting-edge, yet risky, R&D. This chart reflects analysts' overall expectations for the entire metabolic pharma sector. It shows whether experts believe in the commercial success of this revolutionary technology.
Analysts' consensus forecast for the overall market share price
Synlogic is a biotech company developing "live" drugs (synthetic probiotics) to treat rare metabolic diseases. This is an innovative but high-risk field. This chart shows the overall risk appetite in the market. For Synlogic, whose value is based on future hopes, overall market optimism (the rising chart) is critical to funding long-term clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Synlogic Inc.
Synlogic is a pioneer in synthetic biotics. They don't make chemicals, but rather program living bacteria (like E. coli) to consume toxins in the body (to treat rare metabolic diseases like PKU). This chart is a clear indicator of faith in their futuristic R&D. It reflects the market's assessment of their clinical data and their ability to turn living drugs into a commercial reality.
AKIMA Market Segment Index - Pharma metabolism
Synlogic (SYBX) is a pioneer in the field of "living drugs" (Synthetic Biotics)—engineered bacteria designed to treat metabolic diseases like phenylketonuria (PKU) from within the gut. This cutting-edge approach is unique. The graph below shows the average composite index for the entire metabolic pharma segment. It serves as a benchmark for assessing how Synlogic's platform compares to the average market.
The AKIM Index for the overall market
Synlogic is a synthetic biology company that pivoted to strategic alternatives after the failure of a key program. This chart, which reflects the market average, provides a macro backdrop. It helps assess how an asset in liquidation or sale stands against the overall macroeconomic backdrop.
